- In September 2024, Moffitt Cancer Center has partnered with AstraZeneca to fast-track the development of CAR T and TCR T cell therapies. AstraZeneca will gain priority access to Moffitt’s clinical expertise and collaborate closely with physician-scientists, boosting the investigation of innovative cell therapies and enhancing the company’s position in the growing immunotherapy market
- In November 2023, ProKidney Corp. has released positive interim data from its RMCL-002 Phase 2 study, supporting the advancement of its REACT (rilparencel) renal autologous cell therapy for diabetic CKD. This positions the company for late-stage development and has the potential to transform treatment for high-risk diabetic CKD patients, driving further growth and innovation for ProKidney.
Frequently Asked Questions
The market is segmented based on Segmentation, By Therapy Type (Stem Cell Therapy, Exosome Therapy, and Gene Therapy), Cell Source (Autologous Stem Cells and Autologous Kidney Cells), Application (Chronic Kidney Disease (CKD), Acute Kidney Injury (AKI), and Other Kidney Disorders), End-User (Hospitals, Specialty Clinics, and Research Institutes), Distribution Channel (Direct Sales and Online Sales) – Industry Trends and Forecast to 2032
.
The Global Renal Autologous Cell Therapy Market size was valued at USD 380.15 USD Million in 2024.
The Global Renal Autologous Cell Therapy Market is projected to grow at a CAGR of 10.1% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
